Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SU 11654

Known as: SU-11654, SU11654 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

toceranib phosphate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Abstract SY28-01: Spontaneous cancer in dogs: Opportunities for preclinical evaluation of novel therapies
Spontaneous cancers are common in the pet dog population with estimated 60% of dogs that live to 10 years of age developing… Expand
2010
2010
Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
Toceranib phosphate (Palladia, SU11654), an oral tyrosine-kinase inhibitor, is under investigation for the treatment of mast cell… Expand
Review
2010
Review
2010
Abstract IA5-1: Spontaneous cancer in dogs: Opportunities for preclinical investigation of novel therapeutics
Spontaneous cancers occur commonly in the pet dog population. Indeed, an estimated 60% of dogs that live to 10 years of age will… Expand
Review
2010
Review
2010
Distribution, metabolism, and excretion of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in dogs.
Toceranib phosphate (Palladia, SU11654), a multireceptor tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity… Expand
Highly Cited
2009
Highly Cited
2009
Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or…
Purpose: The purpose of this study was to determine the objective response rate (ORR) following treatment of canine mast cell… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Highly Cited
2008
Highly Cited
2008
The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.
OBJECTIVE Mutations of the receptor tyrosine kinase Kit occur in several human and canine cancers. While Kit inhibitors have… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2006
2006
Evaluation of dysregulation of the receptor tyrosine kinases Kit, Flt3, and Met in histiocytic sarcomas of dogs.
OBJECTIVE To evaluate canine histiocytic sarcoma cell lines and tumor samples for dysregulation of the Kit/stem-cell factor (SCF… Expand
Highly Cited
2003
Highly Cited
2003
Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
PURPOSE The purpose of the following study was to investigate the safety and efficacy of the novel multitargeted indolinone… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Highly Cited
2003
Highly Cited
2003
Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
PURPOSE The purpose of this study was to evaluate the effect of the receptor tyrosine kinase inhibitor SU11654 on the activity of… Expand
  • figure 1
  • table 1
  • figure 2
Highly Cited
2002
Highly Cited
2002
Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.
Mutations in the proto-oncogene c-kit, including point mutations, deletions, or duplications in the negative regulatory… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE